公开(公告)号：WO1996040736A1

公开(公告)日：1996-12-19

申请号：PCT/US1996008113

申请日：1996-05-30

Applicant: CELTRIX PHARMACEUTICALS, INC.

Inventor： CELTRIX PHARMACEUTICALS, INC. ,  SOMMER, Andreas ,  OGAWA, Yasushi ,  TAO, Peggy

IPC: C07K01/14

CPC classification number: C07K1/1133 ,  C07K14/4743 ,  C07K14/65

Abstract: The present invention provides a novel method for refolding insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein 3 (IGFBP-3). The method involves mixing of IGF-I and IGFBP-3 together in a cofolding reaction. The inventive cofolding method results in substantially higher yields of correctly folded protein for both molecules and alters the kinetics of refolding. The method includes the production of correctly folded IGF-I, IGFBP-3, and/or IGF-I/IGFBP-3 complex.

Abstract translation: 本发明提供了一种用于重折叠胰岛素样生长因子I（IGF-I）和胰岛素样生长因子结合蛋白3（IGFBP-3）的新方法。 该方法包括在共转化反应中将IGF-1和IGFBP-3混合在一起。 本发明的共轭方法导致两分子的正确折叠的蛋白质的产量显着更高，并且改变重折叠的动力学。 该方法包括产生正确折叠的IGF-I，IGFBP-3和/或IGF-I / IGFBP-3复合物。

公开(公告)号：WO1994017099A2

公开(公告)日：1994-08-04

申请号：PCT/US1994000782

申请日：1994-01-21

Applicant: CELTRIX PHARMACEUTICALS, INC.

Inventor： CELTRIX PHARMACEUTICALS, INC. ,  OGAWA, Yasushi ,  SCHMIDT, David

IPC: C07K07/10

CPC classification number: C07K14/495 ,  A61K38/00 ,  Y10S930/12

Abstract: The invention relates to peptides corresponding to regions of the amino acid sequence of TGF- beta 1 or TGF- beta 2 which retain, either in monomeric or polymeric forms, at least some of the biological activity of the respective full length TGF- beta . The monomeric form of the peptide derived from TGF- beta 1 comprises the following amino acid sequence: CVRQLYIDFRKDLGWKWIHEPKGYHANFCLGP. The monomeric form of the peptide derived from TGF- beta 2 comprises the following amino acid sequence: CLRPLYIDFKRDLGWKWIHEPKGYNANFCAGA. Dimers may be formed via disulfide bonds between the amino-terminal cysteine residues, the carboxy-terminal cysteine residues, or amino- and carboxy-terminal cysteine residues of the monomer subunits.

Abstract translation: 本发明涉及对应于TGF-β1或TGF-β2的氨基酸序列的区域的肽，其以单体或聚合形式保留相应全长TGF-β的至少一些生物活性。 衍生自TGF-β1的肽的单体形式包含以下氨基酸序列：CVRQLYIDFRKDLGWKWIHEPKGYHANFCLGP。 衍生自TGF-β2的肽的单体形式包含以下氨基酸序列：CLRPLYIDFKRDLGWKWIHEPKGYNANFCAGA。 二聚体可以通过氨基末端半胱氨酸残基，羧基末端半胱氨酸残基或单体亚基的氨基和羧基末端半胱氨酸残基之间的二硫键形成。

公开(公告)号：WO1992014481A1

公开(公告)日：1992-09-03

申请号：PCT/US1992001287

申请日：1992-02-14

Applicant: CELTRIX PHARMACEUTICALS, INC.

Inventor： CELTRIX PHARMACEUTICALS, INC. ,  OGAWA, Yasushi ,  SCHMIDT, David, K. ,  ARMSTRONG, Rosa ,  NATHAN, Ranga ,  THOMPSON, Andrea, Y. ,  SEYEDIN, Saeid, M.

IPC: A61K37/02

CPC classification number: C07K14/575 ,  A61K35/28 ,  A61K38/00 ,  A61K38/1841 ,  A61K38/1875 ,  A61L27/227 ,  A61L27/46 ,  A61L27/54 ,  A61L2300/252 ,  A61L2300/414 ,  A61L2300/45 ,  C08L89/06 ,  A61K2300/00

Abstract: Activin is administered systemically and locally to induce the growth of mature bone. Activin enhances the level of bone formation and the quality of the bone formed when administered locally with BMP or bone marrow. Administration of activin by subcutaneous route promotes systemic increase in the bone mass.